Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrumMILATOVIC, Dejan; ZAJA-MILATOVIC, Snjeanna; MONTINE, Kathleen S et al.Journal of neurochemistry. 2003, Vol 87, Num 6, pp 1518-1526, issn 0022-3042, 9 p.Article

Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunitySHIE, Feng-Shiun; MONTINE, Kathleen S; BREYER, Richard M et al.Glia (New York, NY. Print). 2005, Vol 52, Num 1, pp 70-77, issn 0894-1491, 8 p.Article

Proteomics of Human Neurodegenerative DiseasesJING ZHANG; KEENE, C. Dirk; PAN, Catherine et al.Journal of neuropathology and experimental neurology. 2008, Vol 67, Num 10, pp 923-932, issn 0022-3069, 10 p.Article

Therapeutic Targets in Prostaglandin E₂ Signaling for Neurologic DiseaseCIMINO, P. J; KEENE, C. Dirk; BREYER, Richard M et al.Current medicinal chemistry. 2008, Vol 15, Num 19, pp 1863-1869, issn 0929-8673, 7 p.Article

Mercapturate metabolism of 4-hydroxy-2-nonenal in rat and human cerebrumSIDELL, Kathrin R; MONTINE, Kathleen S; PICKLO, Matthew J et al.Journal of neuropathology and experimental neurology. 2003, Vol 62, Num 2, pp 146-153, issn 0022-3069, 8 p.Article

Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicityMAEZAWA, Izumi; JIN, Lee-Way; WOLTJER, Randall L et al.Journal of neurochemistry. 2004, Vol 91, Num 6, pp 1312-1321, issn 0022-3042, 10 p.Article

Mouse cerebral prostaglandins, but not oxidative damage, change with age and are responsive to indomethacin treatmentMONTINE, Kathleen S; MONTINE, Thomas J; MORROW, Jason D et al.Brain research. 2002, Vol 930, Num 1-2, pp 75-82, issn 0006-8993Article

Ecology of the Aging Human BrainSONNEN, Joshua A; SANTA CRUZ, Karen; WHITE, Lon et al.Archives of neurology (Chicago). 2011, Vol 68, Num 8, pp 1049-1056, issn 0003-9942, 8 p.Article

Suppressed Accumulation of Cerebral Amyloid β Peptides in Aged Transgenic Alzheimer's Disease Mice by Transplantation with Wild-Type or Prostaglandin E₂ Receptor Subtype 2-Null Bone MarrowDIRK KEENE, C; CHANG, Rubens C; ROCKHILL, Jason K et al.The American journal of pathology. 2010, Vol 177, Num 1, pp 346-354, issn 0002-9440, 9 p.Article

Role of glutathione in intracellular amyloid-α precursor protein/ carboxy-terminal fragment aggregation and associated cytotoxicityWOLTJER, Randall L; NGHIEM, William; MAEZAWA, Izumi et al.Journal of neurochemistry. 2005, Vol 93, Num 4, pp 1047-1056, issn 0022-3042, 10 p.Article

Suppression of murine cerebral F₂-isoprostanes and F₄-neuroprostanes from excitotoxicity and innate immune response in vivo by α- or γ-tocopherolMILATOVIC, Dejan; VANROLLINS, Mike; KE LI et al.Journal of chromatography. B. 2005, Vol 827, Num 1, pp 88-93, issn 1570-0232, 6 p.Article

Oxidized low-density lipoprotein is present in astrocytes surrounding cerebral infarcts and stimulates astrocyte interleukin-6 secretionSHIE, Feng-Shiun; NEELY, M. Diana; MAEZAWA, Izumi et al.The American journal of pathology. 2004, Vol 164, Num 4, pp 1173-1181, issn 0002-9440, 9 p.Article

Antioxidants significantly affect the formation of different classes of isoprostanes and neuroprostanes in rat cerebral synaptosomesMONTINE, Thomas J; MONTINE, Kathleen S; REICH, Erin E et al.Biochemical pharmacology. 2003, Vol 65, Num 4, pp 611-617, issn 0006-2952, 7 p.Article

Cerebrospinal fluid Aβ₄₂, tau, and F₂-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controlsMONTINE, Thomas J; KAYE, Jeffery A; MONTINE, Kathleen S et al.Archives of pathology & laboratory medicine (1976). 2001, Vol 125, Num 4, pp 510-512, issn 0363-0153Article